247 related articles for article (PubMed ID: 2274626)
1. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
Chouinard G; Goodman W; Greist J; Jenike M; Rasmussen S; White K; Hackett E; Gaffney M; Bick PA
Psychopharmacol Bull; 1990; 26(3):279-84. PubMed ID: 2274626
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression.
Reimherr FW; Chouinard G; Cohn CK; Cole JO; Itil TM; LaPierre YD; Masco HL; Mendels J
J Clin Psychiatry; 1990 Dec; 51 Suppl B():18-27. PubMed ID: 2258378
[TBL] [Abstract][Full Text] [Related]
3. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
[TBL] [Abstract][Full Text] [Related]
5. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.
Greist JH; Jefferson JW; Kobak KA; Chouinard G; DuBoff E; Halaris A; Kim SW; Koran L; Liebowtiz MR; Lydiard B
Int Clin Psychopharmacol; 1995 Jun; 10(2):57-65. PubMed ID: 7673657
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
[TBL] [Abstract][Full Text] [Related]
7. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo.
Jenike MA; Baer L; Summergrad P; Minichiello WE; Holland A; Seymour R
Am J Psychiatry; 1990 Jul; 147(7):923-8. PubMed ID: 2192564
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients.
Cohn CK; Shrivastava R; Mendels J; Cohn JB; Fabre LF; Claghorn JL; Dessain EC; Itil TM; Lautin A
J Clin Psychiatry; 1990 Dec; 51 Suppl B():28-33. PubMed ID: 2258379
[TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.
Kronig MH; Apter J; Asnis G; Bystritsky A; Curtis G; Ferguson J; Landbloom R; Munjack D; Riesenberg R; Robinson D; Roy-Byrne P; Phillips K; Du Pont IJ
J Clin Psychopharmacol; 1999 Apr; 19(2):172-6. PubMed ID: 10211919
[TBL] [Abstract][Full Text] [Related]
10. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
Sevincok L; Topuz A
J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of aqueous extract of Echium amoenum in treatment of obsessive-compulsive disorder.
Sayyah M; Boostani H; Pakseresht S; Malaieri A
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1513-6. PubMed ID: 19737592
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.
Pigott TA; L'Heureux F; Rubenstein CS; Bernstein SE; Hill JL; Murphy DL
J Clin Psychopharmacol; 1992 Jun; 12(3):156-62. PubMed ID: 1629380
[TBL] [Abstract][Full Text] [Related]
13. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
Mowla A; Boostani S; Dastgheib SA
J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
[TBL] [Abstract][Full Text] [Related]
15. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J
Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637
[TBL] [Abstract][Full Text] [Related]
16. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Rabinowitz I; Baruch Y; Barak Y
Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults.
Greenberg WM; Benedict MM; Doerfer J; Perrin M; Panek L; Cleveland WL; Javitt DC
J Psychiatr Res; 2009 Mar; 43(6):664-70. PubMed ID: 19046587
[TBL] [Abstract][Full Text] [Related]
18. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo.
Fabre LF; Abuzzahab FS; Amin M; Claghorn JL; Mendels J; Petrie WM; Dubé S; Small JG
Biol Psychiatry; 1995 Nov; 38(9):592-602. PubMed ID: 8573661
[TBL] [Abstract][Full Text] [Related]
19. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
20. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.
Rasmussen S; Hackett E; DuBoff E; Greist J; Halaris A; Koran LM; Liebowitz M; Lydiard RB; McElroy S; Mendels J; O'Connor K
Int Clin Psychopharmacol; 1997 Nov; 12(6):309-16. PubMed ID: 9547132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
